Ambrisentan Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast - 2022 to 2028

The global ambrisentan market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ambrisentan is used alone or in combination with tadalafil to treat pulmonary arterial hypertension. Ambrisentan may improve the ability to exercise and slow the worsening of symptoms in people with pulmonary arterial hypertension. The global ambrisentan market is growing due to the risingprevalence of pulmonary arterial hypertension disease globally. According to theNational Organization for Rare Disorders, pulmonary arterial hypertension is 3-5 times more prevalent in females than males. The age group of the females diagnosed with pulmonary arterial hypertension is between 30-60 years. It has been estimated that one to two individual out of one million is diagnosed with pulmonary arterial hypertension in the US. Almost 500-1000 new cases are registered every year in US and Europe who are diagnosed with pulmonary arterial hypertension. According to the American Journal of Physiology, it is estimated that almost 1% of the global population is already affected by pulmonary arterial hypertension.

A full report of Ambrisentan Market is available at:https://orionmarketreports.com/ambrisentan-market/104358/

The market players are alsocontributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

In May 2019, Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of ambrisentan tablets in the US market for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening.
In April 2019, Cipla Inc. announced its final approval for the Abbreviated New Drug Application (ANDA) for ambrisentan tablets in 5mg and 10mg variants from the USFDA for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening.
In March 2019, Zydus Group received approval from the USFDA to market ambrisentan tablets in 5 mg and 10 mg variant for the treatment of high blood pressure.

Market Coverage

The market number available for - 2022-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape- Mylan N.V., Pfizer Inc., Cipla Inc., and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Ambrisentan Market Report by Segment

By Application

Pulmonary Disorder
Cardiac Disorder

 

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.